[ANIP] ANI Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 622.64 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 63.26 Change: 0.76 (1.22%)
Ext. hours: Change: 0 (0%)

chart ANIP

Refresh chart

Description: ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid lithium carbonate extended release tablets. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company offers generic products, including Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema for the treatment of ulcerative colitis; Metoclopramide syrup for treating heartburn symptoms with gastroesophageal reflux disease; and Opium Tincture to treat severe diarrhea by slowing the movement of the intestines, as well as branded p

Fundamental Ratios
Shares Outstanding11.49 M EPS0.7 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 182.82% Sales Growth - Q/Q-10.64% P/E64.69
P/E To EPS Growth P/S9.75 P/BV4.3 Price/Cash Per Share
Price/Free Cash Flow29.77 ROA11.19% ROE20.56% ROI
Current Ratio22.37 Quick Ratio21.19 Long Term Debt/Equity Debt Ratio0.06
Gross Margin81.84% Operating Margin40.83% Net Profit Margin46.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities20 K Cash From Investing Activities-4.61 M Cash From Operating Activities1.12 M Gross Profit16.05 M
Net Profit4.37 M Operating Profit9.57 M Total Assets265.99 M Total Current Assets202.99 M
Total Current Liabilities9.07 M Total Debt112.17 M Total Liabilities121.25 M Total Revenue18.8 M
Technical Data
High 52 week74.56 Low 52 week41.17 Last close60.78 Last change0.7%
RSI73.85 Average true range1.73 Beta0.82 Volume99.67 K
Simple moving average 20 days6.06% Simple moving average 50 days15.18% Simple moving average 200 days1.77%
Performance Data
Performance Week-0.2% Performance Month14.27% Performance Quart4.85% Performance Half-11.04%
Performance Year26.07% Performance Year-to-date35.01% Volatility daily1.61% Volatility weekly3.6%
Volatility monthly7.37% Volatility yearly25.53% Relative Volume340.74% Average Volume72.78 K
New High New Low


2019-09-12 06:57:22 | ANI Pharmaceuticals NASDAQ:ANIP Takes On Some Risk With Its Use Of Debt

2019-09-11 08:30:00 | ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL

2019-09-05 18:43:38 | Edited Transcript of ANIP earnings conference call or presentation 7-Aug-19 2:30pm GMT

2019-08-13 08:08:24 | ANI Pharmaceuticals, Inc. NASDAQ:ANIP Delivered A Weaker ROE Than Its Industry

2019-08-07 13:23:43 | ANI Pharmaceuticals Inc ANIP Q2 2019 Earnings Call Transcript

2019-08-07 09:45:01 | ANI Pharmaceuticals ANIP Q2 Earnings Surpass Estimates

2019-08-07 08:30:00 | ANI Pharmaceuticals Reports Second Quarter Results

2019-07-31 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results

2019-07-30 10:38:02 | ANI Pharmaceuticals ANIP Earnings Expected to Grow: What to Know Ahead of Q2 Release

2019-07-09 14:38:09 | How Much is ANI Pharmaceuticals, Inc.'s NASDAQ:ANIP CEO Getting Paid?

2019-06-27 16:11:02 | Hedge Funds Piled Into This Stock Right Before Its Double Digit Gains

2019-06-25 08:30:00 | ANI Pharmaceuticals Announces Launch of Ranitidine Capsules

2019-06-20 10:30:00 | ANI Pharmaceuticals Announces Approval of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5ml

2019-06-18 08:00:00 | ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc.

2019-06-12 08:30:00 | ANI Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference

2019-05-31 12:38:43 | Is ANI Pharmaceuticals, Inc. NASDAQ:ANIP Trading At A 48% Discount?

2019-05-16 09:00:01 | What Makes ANI ANIP a New Buy Stock

2019-05-10 10:23:20 | ANI Pharmaceuticals Inc ANIP Q1 2019 Earnings Call Transcript

2019-05-10 01:49:37 | Edited Transcript of ANIP earnings conference call or presentation 9-May-19 2:30pm GMT

2019-05-09 13:14:53 | Did Hedge Funds Drop The Ball On ANI Pharmaceuticals Inc ANIP ?

2019-05-09 08:39:31 | ANI: 1Q Earnings Snapshot

2019-05-09 08:30:00 | ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance

2019-05-02 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results

2019-05-01 17:45:09 | ANI Pharmaceuticals ANIP Dips More Than Broader Markets: What You Should Know

2019-04-30 09:00:01 | The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

2019-04-30 08:32:12 | What's in Store for ANI Pharmaceuticals ANIP Q1 Earnings?

2019-04-29 08:05:12 | American Economy Hits the Gas: 5 Top Gainers

2019-04-27 09:04:32 | If You Had Bought ANI Pharmaceuticals NASDAQ:ANIP Shares Five Years Ago You'd Have Made 115%

2019-04-26 11:11:03 | Medicines Company MDCO Q1 Loss Narrows, Inclisiran in Focus

2019-04-25 17:45:09 | ANI Pharmaceuticals ANIP Dips More Than Broader Markets: What You Should Know

2019-04-25 09:31:01 | Alexion ALXN Q1 Earnings Beat Estimates, Guidance Raised

2019-04-23 09:34:01 | Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide

2019-04-22 09:12:01 | 5 Stocks With Recent Price Strength to Enhance Your Returns

2019-04-18 17:50:09 | ANI Pharmaceuticals ANIP Stock Sinks As Market Gains: What You Should Know

2019-04-17 08:14:12 | Ultragenyx's RARE UX007 Gets Fast Track Status by FDA

2019-04-16 10:54:02 | QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

2019-04-15 09:30:01 | Has ANI Pharmaceuticals ANIP Outpaced Other Medical Stocks This Year?

2019-04-15 08:45:12 | 3 Reasons Why Growth Investors Shouldn't Overlook ANI ANIP

2019-04-15 08:30:00 | ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product

2019-04-12 17:45:09 | ANI Pharmaceuticals ANIP Outpaces Stock Market Gains: What You Should Know

2019-04-12 09:46:01 | 5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

2019-04-11 10:43:02 | Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

2019-04-11 09:34:01 | BioDelivery BDSI Buys US Rights to Pain Drug for $30M

2019-04-10 09:30:01 | Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

2019-04-09 11:24:03 | PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

2019-04-09 08:41:12 | Coherus CHRS Catches Eye: Stock Jumps 6.9%

2019-04-08 08:45:12 | Seattle Genetics SGEN Surges: Stock Moves 7.6% Higher

2019-04-05 17:50:09 | ANI Pharmaceuticals ANIP Stock Sinks As Market Gains: What You Should Know

2019-04-05 10:46:02 | Palatin Technologies PTN in Focus: Stock Moves 5.7% Higher

2019-04-05 08:53:12 | The Zacks Analyst Blog Highlights: ANI Pharmaceuticals, Avianca, Avid, Terex and Encore Wire